Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

This World Infertility Awareness Month, Organon Canada is committed to listening and highlighting different paths and barriers to parenthood

One in six Canadians experiences infertility; Organon Canada continues to work with partners to advocate for patients for increased access to care

KIRKLAND, QC, June 17, 2022 /CNW/ - Organon Canada, a subsidiary of Organon (NYSE: OGN) a global women's healthcare company, recognizes this World Infertility Awareness Month as an opportunity to highlight the importance of access to reproductive healthcare. Through listening and empowering aspiring parents, Organon aims to:

Organon Canada logo (CNW Group/Organon Canada Inc.)

  • Acknowledge and bring light to the barriers to fertility
  • Help break down barriers to fertility
  • Advocate for and support aspiring parents through their unique journey to creating a family.

Roughly 1 in 6 Canadian couples experiences infertility[i], and often, the women bear the burden of stigma and blame, even though people of all genders can experience it[ii]. Organon encourages those who have experienced - or continue to experience - barriers to fertility to speak openly if comfortable to help break the stigma and raise awareness for those striving to create the family they desire.

"We know the fertility journey can encompass a range of emotional, physical, clinical, financial, and legal twists and turns, and rarely follows one straight path. We are committed to improving the fertility experience for aspiring parents facing challenges conceiving," said Amy Cairns, Executive Director, Women's Health & Established Brands at Organon Canada.

With the help of innovations in reproductive medicine, such as in-vitro fertilization (IVF,) intracytoplasmic sperm injection (ICSI,) intrauterine insemination (IUI,) egg and sperm donation, egg freezing and surrogacy, an increasing number of families around the world can grow.

Canadians should be able to grow their family, despite their location, financial circumstance, sexual orientation, gender, relationship status or cultural background. Connecting with others who have experienced or are experiencing similar barriers can help identify the right approach and next steps in their journey.

"Fertility Matters Canada is dedicated to empowering Canadians to reach their reproductive health goals by providing support, awareness, information and education and promoting equal access to fertility treatments," said Carolynn Dubé, Executive Director of Fertility Matters Canada. "As we look to continue raising awareness, working alongside various partners such as Organon Canada helps strengthen our voices and patient experience. Together we are one step closer to breaking down barriers to fertility."

Along with Fertility Matters Canada, Organon firmly advocates for an inclusive and personalized approach to fertility treatment, care and support, regardless of sexual orientation and marital status.

For more information on infertility awareness and the work Organon is doing to support aspiring parents in Canada, visit www.organon.ca.

For more information on support groups and the work Fertility Matters Canada is doing to support those experiencing barriers to fertility in Canada, visit www.fertilitymatters.ca.

About Organon

Organon is a global healthcare company formed through a spin-off from Merck, (NYSE: MRK) known as MSD outside of the United States and Canada, to focus on improving the health of women throughout their lives. Organon has a portfolio of more than 60 medicines and products across a range of therapeutic areas. Led by the women's health portfolio coupled with an expanding biosimilars business and stable franchise of established medicines, Organon's products produce strong cash flows that will support investments in innovation and future growth opportunities in women's health. In addition, Organon is pursuing opportunities to collaborate with biopharmaceutical innovators looking to commercialize their products by leveraging its scale and presence in fast growing international markets.

Organon has a global footprint with significant scale and geographic reach, world-class commercial capabilities, and approximately 9,500 employees with headquarters located in Jersey City, New Jersey.

For more information, www.organon.ca and connect with us on LinkedIn and Twitter.

_________________________

i Government of Canada. Infertility. Accessed: May 30, 2022. Available at https://www.canada.ca/en/public-health/services/fertility/fertility.html

ii Thoma M, Fledderjohann J, Cox C, Kantum Adageba R. Biological and Social Aspects of Human Infertility: A Global Perspective. Oxford Encyclopedia of Sexual and Reproductive Health. 2021. doi:https://doi.org/10.1093/acrefore/9780190632366.013.184

SOURCE Organon Canada Inc.

Cision View original content to download multimedia: http://www.newswire.ca/en/releases/archive/June2022/17/c4257.html

Tags:


Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today